Randomized Controlled Trials in Hereditary Cancer Syndromes

Chethan Ramamurthy, Yana Chertock, Michael J. Hall

Research output: Contribution to journalReview articlepeer-review


Conducting randomized controlled trials (RCTs) in patients with germline mutations in genes that predispose to adult-onset cancer is hampered by the rarity of these mutations, barriers to their identification, and challenges inherent to randomizing high-risk individuals as part of a clinical trial. Most of the clinically relevant RCTs have been conducted in 3 syndromes in only some of the high-risk genes for which clinical testing is currently available. This article reviews the surgical, screening, and chemoprevention RCTs in each of the syndromes in clinically relevant studies conducted in the past 10 years.

Original languageEnglish (US)
Pages (from-to)729-750
Number of pages22
JournalSurgical Oncology Clinics of North America
Issue number4
StatePublished - Oct 2017
Externally publishedYes


  • Clinical trials
  • FAP
  • Germline mutations
  • HBOC
  • Hereditary cancer syndromes
  • Lynch

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Randomized Controlled Trials in Hereditary Cancer Syndromes'. Together they form a unique fingerprint.

Cite this